Bisphosphonates are drugs that inhibit mineralization or resorption of the bone by blocking the action of osteoclasts. Bisphosphonates are enzyme-resistant analogues of pyrophosphate, which normally inhibits mineralization in the bone. Their effect is dose dependent and they reduce the turnover of bone by inhibiting recruitment and promoting apoptosis of osteoclasts. Bisphosphonates are used to treat postmenopausal and glucocorticoid induced osteoporosis, Paget's disease of bone and malignant hypercalcemia.

The global Bisphosphonate Drug market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Bisphosphonate Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Bisphosphonate Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Bisphosphonate Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Bisphosphonate Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Merck
Teva
Mylan
Apotex Corp
Cobalt Pharmaceuticals
Genentech
Novartis Pharmaceuticals
Sanofi-Aventis

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Alendronate
Risedronate
Zoledronic acid
Other Bisphosphonate Drug

Segment by Application
Postmenopausal osteoporosis
Men with osteoporosis
Paget’s disease
Bone loss caused by cancer treatment
Osteoporosis imperfecta in children